PAO Group, Inc. (USOTC: PAOG) today announced engaging Saul Kaye the founder of iCAN ( www.israel-cannabis.com ) and CannaTech ( www.canna-tech.co ) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contra
| SANDUSKY, Ohio, Oct. 1, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). Saul is a licensed pharmacist and a serial entrepreneur with both retail and e-commerce experience. He has founded multiple companies spanning six countries across the US, Europe, Israel and Australia. Saul Kaye is a global influencer in the medical cannabis industry, a widely respected speaker on cannabis industry movements and has been engaged in the past by other notable cannabis industry participants including Alvit, Canopy Growth, Altria and many other global cannabis companies. On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results. The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals’ cannabinoid treatments, shed light on PAOG’s wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx. One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells. CBD Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/ THC Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/ In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG’s RespRx overall technology. The growing body of cannabis research is building convincing evidence behind how specific cannabinoids can beneficially impact specific immune responses. The research behind RespRx demonstrates how the process to derive RespRx can be manipulated to target specific cannabinoid extractions. Accordingly, as advancing cannabis research unveils further evidence behind how specific cannabinoids beneficially impact specific immune responses, PAOG is optimistic that it can utilize its overall cannabis extraction process to effectively derive formals with high concentrations of target cannabinoids. Hence, PAOG sees a more broad future of developing cannabis treatments beyond COPD. In conjunction with PAOG’s acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (USOTC: PURA) to develop a proprietary cultivar to support PAOG’s cannabis pharmaceutical treatment objectives. PAOG has announced plans with PURA to expand upon PAOG’s hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA’s Farmersville Brands initiative. PAOG’s Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative. PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA’s year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment. Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release. CONTACT INFORMATION Contact Us:
SOURCE PAO Group, Inc. | ||
Company Codes: OtherOTC:PAOG, OTC-PINK:PAOG, OTC-QX:PAOG, OTC-QB:PAOG |
View original content:
